Imagion Biosystems (ASX:IBX) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems ROE % Adjusted to Book Value?

Imagion Biosystems's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Imagion Biosystems's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Imagion Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

Imagion Biosystems ROE % Adjusted to Book Value Historical Data

The historical data trend for Imagion Biosystems's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems ROE % Adjusted to Book Value Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.02

-7.18

-18.97

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial											-21.74	-	-	-	-

Competitive Comparison of Imagion Biosystems's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Imagion Biosystems's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Imagion Biosystems ROE % Adjusted to Book Value Calculation

Imagion Biosystems's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Imagion Biosystems's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Imagion Biosystems ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Imagion Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IBXXF:USA

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines